Introduction Estrogen receptor (ER) signaling and its interaction with epidermal growth factor
receptor (EGFR) is a potential therapeutic target in non–small-cell lung cancer (NSCLC). To …

Identifying new effective therapeutic treatments for lung cancer is critical to improving overall
patient survival. We have targeted both the estrogen receptor (ER) and the epidermal growth …

Objectives This open-label, randomized phase II trial evaluated antitumor efficacy of an
antiestrogen, fulvestrant, in combination with human epidermal growth factor receptor …

INTRODUCTION: Estrogen receptor beta (ERβ) has been detected in non-small cell lung
cancer (NSCLC) cell lines and tumor specimens. The ER down-regulator, fulvestrant …

Background: EGFR inhibition is an established therapy for previously treated NSCLC.
Estrogen receptors (ER) and aromatase are expressed in most NSCLC specimens in both …

Lung cancer is the most common cause of cancer mortality in male and female patients in
the US. The etiology of non-small cell lung cancer (NSCLC) is not fully defined, but new data …

Lung cancer (LC) is the leading cause of cancer death in men worldwide and has
significantly increased in women. Differences in non-small cell lung cancer (NSCLC) …

Simple Summary Exogenous and endogenous estrogens and associated receptors
modulate signaling pathways with biochemical events implicated in non-small cell lung …

Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related deaths
worldwide. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR‑TKIs) have …

Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is approved
for clinical use in the treatment of non-small cell lung cancer (NSCLC). According to …